Medtronic and ChristianaCare Collaborate to Improve Patient Outcomes and Reduce Cost of Care in Delaware
December 16 2019 - 8:00AM
Medtronic plc (NYSE:MDT) and ChristianaCare today announced a
collaboration designed to improve outcomes for ChristianaCare
patients in Delaware and the surrounding region. The five-year
agreement will focus on developing and deploying value-based
healthcare initiatives to help ChristianaCare apply the right
medical technologies and therapies to patients who may benefit
most, with shared financial accountability between ChristianaCare
and Medtronic to improve patient outcomes while reducing the cost
of care.
“There’s general consensus that a fee-for-service
system is not sustainable, and a value-based system is the way to
go, but ‘how’ becomes a question. We want to take that on, but
transformation can only happen through collaboration with others
with aligned views and aligned reward mechanisms,” said Omar
Ishrak, chairman and chief executive officer of Medtronic.
“ChristianaCare’s shared commitment to developing value-based
healthcare initiatives makes them an ideal partner for
Medtronic.”
“We are committed to delivering health — not just
healthcare — to the people we serve,” said Janice E. Nevin, M.D.,
MPH, president and chief executive officer of ChristianaCare.
“Value-based care is the key to achieving optimal health and an
exceptional experience for the people we serve, while ensuring that
care is accessible and affordable.”
One of the first initiatives is expected to
address opioid-induced ventilatory impairment (OIVI), which occurs
when opioids used for pain management inhibit the central drive to
breathe and may cause the patient to stop breathing completely
unless clinicians intervene with life-saving measures. Medtronic
and ChristianaCare seek to standardize an enhanced respiratory
monitoring initiative to help address OIVI. This initiative will be
designed to identify patients receiving opioids for pain management
who are at high risk for OIVI and apply continuous monitoring
technology to track breathing, and help alert the care team to
abnormal trends.
Other initiatives are expected to address heart
failure and diabetes, which together affect more than 35 million
people in the United States and cost the nation an estimated $357
billion each year, according to the Centers for Disease Control and
Prevention.1,2 This work is designed to enhance
ChristianaCare’s ability to prevent or slow disease progression,
reduce hospitalizations, and lower overall cost of care for
patients with these chronic conditions.
“Together with Medtronic, we are aligning
expertise and incentives to exponentially increase our ability to
achieve optimal health — not just better care delivery,” said
Randall Gaboriault, M.S., chief digital and information officer and
senior vice president, innovation and strategic development at
ChristianaCare. “This collaboration will implement a new value
chain, based on vested purpose, co-innovation, digital and
data.”
Learnings from this collaboration have the
potential to impact health far beyond the Delaware region.
Delaware’s demographics and ChristianaCare’s diverse patient
population across a broad spectrum of healthcare settings create an
ideal test ground for the organizations to develop and scale new
value-based initiatives that could benefit the health of patient
populations across the country.
“We recognize that creating healthier communities
requires integrated care models, passion to improve the status quo,
and an aligned purpose of helping patients live healthier and
fuller lives,” said John Liddicoat, M.D., executive vice
president and president of the Americas Region at Medtronic. “This
collaboration with ChristianaCare reinforces our joint commitment
to healthcare innovation through value-based arrangements.”
About ChristianaCareHeadquartered in
Wilmington, Delaware, ChristianaCare is one of the country’s most
dynamic health care organizations, centered on improving health
outcomes, making high-quality care more accessible and lowering
health care costs. ChristianaCare includes an extensive network of
outpatient services, home health care, medical aid units, two
hospitals (1,227 beds), a Level I trauma center and a Level III
neonatal intensive care unit, a comprehensive stroke center and
regional centers of excellence in heart and vascular care, cancer
care and women’s health. It also includes the pioneering Gene
Editing Institute and was rated by IDG Computerworld as one of the
nation’s Best Places to Work in IT. ChristianaCare is a
not-for-profit teaching health system with more than 260 residents
and fellows. We are continually ranked by US News & World
Report as a Best Hospital. With our unique, data-powered CareVio
care coordination service and a focus on population health and
value-based care, ChristianaCare is shaping the future of health
care. Learn how we deliver greater quality and value
at https://christianacare.org.
About MedtronicMedtronic plc
(www.medtronic.com), headquartered in Dublin, Ireland, is among the
world’s largest medical technology, services and solutions
companies – alleviating pain, restoring health and extending life
for millions of people around the world. Medtronic employs more
than 90,000 people worldwide, serving physicians, hospitals and
patients in more than 150 countries. The company is focused on
collaborating with stakeholders around the world to take health
care Further, Together.
Any forward-looking statements are subject to
risks and uncertainties such as those described in Medtronic's
periodic reports on file with the Securities and Exchange
Commission. Actual results may differ materially from anticipated
results.
-end-
1 CDC Heart Failure Fact
Sheet: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm
2 CDC Diabetes Quick
Facts: https://www.cdc.gov/diabetes/basics/diabetes.html
Laura GriffithMedtronic plcPublic Relations+1-763-505-5598
Ryan WeispfenningMedtronic plcInvestor
Relations+1-763-505-4626
Shane HoffmanChristianaCare+1-302-327-3324
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024